Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

PURPOSE: The JFMC33-0502 trial is a phase III clinical study designed to determine the most appropriate duration of postoperative adjuvant chemotherapy with uracil–tegafur (UFT) plus leucovorin in patients with stage IIB or III colon cancer. We report the interim results of preplanned safety analyse...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Tsuchiya, Takashi, Sadahiro, Sotaro, Sasaki, Kazuaki, Kondo, Ken, Katsumata, Kenji, Nishimura, Genichi, Kakeji, Yoshihiro, Baba, Hideo, Morita, Takayuki, Koda, Keiji, Sato, Seiji, Matsuoka, Junji, Yamaguchi, Yoshiyuki, Usuki, Hisashi, Hamada, Chikuma, Kodaira, Susumu, Saji, Shigetoyo
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer Berlin Heidelberg 2014
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4032639/
https://ncbi.nlm.nih.gov/pubmed/24744162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2461-5
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים